Summary

• Study directors:
  • Adam Boxer, MD, PhD
  • Bruce Miller, MD
• Sponsor: Forest Research Institute
• Recruiting?: Yes
• Official study title: A Prospective, Randomized, Multi-Center, Double-Blind, 26 Week, Placebo-Controlled Trial of Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia
• ClinicalTrials.gov identifier: NCT00545974
• Conditions studied: Frontotemporal dementia (FTD) and semantic dementia (SD)
• Intervention: 10 mg of memantine or placebo taken twice-daily
• Purpose: The study is designed to determine whether memantine is effective in slowing the rate of behavioral decline in frontotemporal dementia. The study will also assess the safety and tolerability of long-term treatment with memantine in patients with frontotemporal dementia (FTD) or semantic dementia (SD); whether memantine is effective in slowing the rate of cognitive decline in frontotemporal dementia; and evaluate whether memantine delays or decreases the emergence of parkinsonism in frontotemporal dementia. Lastly, the study is designed to determine whether treatment with memantine affects change in weight.